Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of NOACs in Patients with Liver Disease: Multicenter Cohort
ChiCTR2500108769Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban in chronic liver disease (CLD) and None (2 arms), sponsored by Beijing Hospital. Primary endpoints: Thromboembolic events and Bleeding events. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
chronic liver disease (CLD)
Beyond the preview
Go deeper on ChiCTR2500108769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108769.